Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 0.67 -2.66% -0.02
ARDS closed up 2.56 percent on Friday, February 3, 2023, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup -2.66%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.66%
NR7 Range Contraction -2.66%
Narrow Range Bar Range Contraction -2.66%
Inside Day Range Contraction -2.66%
Wide Bands Range Expansion -2.66%
Oversold Stochastic Weakness -2.66%
1,2,3 Retracement Bearish Bearish Swing Setup -0.16%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.16%
Calm After Storm Range Contraction -0.16%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 6 hours ago
Down 2 % about 6 hours ago
Down 1% about 6 hours ago
Down 1% 3 days ago
Up 2% 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aridis Pharmaceuticals Inc. Description

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immune System Infectious Diseases Immunotherapy Antibodies Monoclonal Antibody Monoclonal Antibodies Infection Bacterial Infections Bacterial Disease Pneumonia Staphylococcus Aureus Pathogenic Bacteria Human Monoclonal Antibodies Drug Resistance Pseudomonas Aeruginosa Targeted Immunotherapy Immunoglobulin M

Is ARDS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.94
52 Week Low 0.5722
Average Volume 1,021,815
200-Day Moving Average 1.22
50-Day Moving Average 1.03
20-Day Moving Average 1.05
10-Day Moving Average 0.82
Average True Range 0.19
RSI 37.50
ADX 36.31
+DI 8.65
-DI 28.14
Chandelier Exit (Long, 3 ATRs) 1.08
Chandelier Exit (Short, 3 ATRs) 1.14
Upper Bollinger Bands 1.61
Lower Bollinger Band 0.50
Percent B (%b) 0.17
BandWidth 105.72
MACD Line -0.12
MACD Signal Line -0.06
MACD Histogram -0.0595
Fundamentals Value
Market Cap 6.93 Million
Num Shares 10.1 Million
EPS -4.19
Price-to-Earnings (P/E) Ratio -0.16
Price-to-Sales 58.17
Price-to-Book 5.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.73
Resistance 3 (R3) 0.73 0.71 0.73
Resistance 2 (R2) 0.71 0.70 0.71 0.72
Resistance 1 (R1) 0.70 0.69 0.69 0.70 0.72
Pivot Point 0.68 0.68 0.67 0.68 0.68
Support 1 (S1) 0.67 0.67 0.66 0.67 0.66
Support 2 (S2) 0.65 0.66 0.65 0.65
Support 3 (S3) 0.64 0.65 0.65
Support 4 (S4) 0.64